Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunomodulation by targeted anticancer agents
Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, et al.
Cancer Cell (2020) Vol. 39, Iss. 3, pp. 310-345
Open Access | Times Cited: 179

Showing 26-50 of 179 citing articles:

Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Lenka Kašíková, Jana Raková, Michal Hensler, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 29
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
Elisabete Cruz Da Silva, Marie-Cécile Mercier, Nelly Étienne-Selloum, et al.
Cancers (2021) Vol. 13, Iss. 8, pp. 1795-1795
Open Access | Times Cited: 96
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Tao Jiang, Pingyang Wang, Jie Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 74
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy
Wenjun Xiong, Yang Gao, Wenyi Wei, et al.
Trends in cancer (2021) Vol. 7, Iss. 9, pp. 837-846
Closed Access | Times Cited: 65
Myeloid-Derived Suppressor Cells and Radiotherapy
Carlos Jiménez‐Cortegana, Claudia Galassi, Vanessa Klapp, et al.
Cancer Immunology Research (2022) Vol. 10, Iss. 5, pp. 545-557
Open Access | Times Cited: 55
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
Robby Barnestein, Loïck Galland, Laura Kalfeist, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 54
Monocyte programming by cancer therapy
М. Р. Патышева, A. A. Frolova, Irina Larionova, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 43
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
Safae Terrisse, Anne‐Gaëlle Goubet, Kousuke Ueda, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004191-e004191
Open Access | Times Cited: 42
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
Nannan Zhang, Yanping Gao, Zhengrong Huang, et al.
Cancer Letters (2022) Vol. 545, pp. 215852-215852
Closed Access | Times Cited: 42
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
Lukáš Rob, David Cibula, Paweł Knapp, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003190-e003190
Open Access | Times Cited: 39
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Jiaojiao Ni, Zizhen Zhang, Ming-jie Ge, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 2, pp. 288-307
Open Access | Times Cited: 39
BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Liwei Zhao, Peng Liu, Misha Mao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2448-2469
Open Access | Times Cited: 30
AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer
Zikun Ma, Zhiyong Li, Yize Mao, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Khine Shan, Amalia Bonano-Rios, Nyein Wint Yee Theik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 1973-1973
Open Access | Times Cited: 11
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
Yunong Xie, Haofeng Wu, Yimiao He, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 9
Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity
Liming Gui, Kaiwen W. Chen, Jingjing Yan, et al.
Cell Reports Medicine (2025), pp. 101913-101913
Open Access | Times Cited: 1
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Gabriele Antonarelli, Chiara Corti, Paolo Tarantino, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1537-1551
Open Access | Times Cited: 52
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Jitka Fučíková, An Coosemans, Sandra Oršulić, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 10, pp. e002873-e002873
Open Access | Times Cited: 45
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
Jana Raková, Iva Truxová, Peter Holíček, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 42
DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis
Maria V. Vedunova, Victoria D. Turubanova, Olga Vershinina, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 12
Open Access | Times Cited: 30
Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer
Léa Montégut, Rafael de Cabo, Laurence Zitvogel, et al.
Cancer Discovery (2022) Vol. 12, Iss. 10, pp. 2258-2279
Open Access | Times Cited: 29
Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy
Sihui Yu, Hongyang Xiao, Li Ma, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 5, pp. 188946-188946
Closed Access | Times Cited: 19
Molecular determinants of immunogenic cell death elicited by radiation therapy
Claudia Galassi, Vanessa Klapp, Takahiro Yamazaki, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 20-32
Open Access | Times Cited: 19
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
Emily K. Kleczko, Anh T. Le, Trista K. Hinz, et al.
Cancer Letters (2023) Vol. 556, pp. 216062-216062
Open Access | Times Cited: 17
Oleic Acid Dissolves cGAS–DNA Phase Separation to Inhibit Immune Surveillance
Lina Wang, Qiaoling Liu, Na Wang, et al.
Advanced Science (2023) Vol. 10, Iss. 14
Open Access | Times Cited: 16

Scroll to top